Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A type of trimethylaminuria that occurs as the result of treatment with large doses of dietary precursors of the offending chemical. Symptoms develop when the ability of the liver enzyme (flavin-containing monooxygenase 3) is insufficient to break down (metabolize) the excess trimethylamine.
No clinical trials have been registered for secondary trimethylaminuria.
5 publications have been identified in PubMed for secondary trimethylaminuria. Research spans Case Report / Case Series (60%) and Review / Meta-Analysis (40%).
Salahi A (2025). [PMID: 40028749](https://pubmed.ncbi.nlm.nih.gov/40028749/). *Vet Med Sci*. [Review / Meta-Analysis]
Dercksen M (2025). [PMID: 40078825](https://pubmed.ncbi.nlm.nih.gov/40078825/). *JIMD Rep*. [Case Report / Case Series]
Knapp M (2025). [PMID: 40636240](https://pubmed.ncbi.nlm.nih.gov/40636240/). *Eur J Case Rep Intern Med*. [Case Report / Case Series]
Resende MM (2025). [PMID: 40125190](https://pubmed.ncbi.nlm.nih.gov/40125190/). *Cureus*. [Case Report / Case Series]
Sidoti A (2024). [PMID: 39765628](https://pubmed.ncbi.nlm.nih.gov/39765628/). *Biology (Basel)*. [Review / Meta-Analysis]
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 12:49 AM UTC